Detalhe da pesquisa
1.
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
Cancer
; 130(9): 1693-1701, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165808
2.
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Cancer
; 130(4): 541-552, 2024 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843249
3.
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.
Future Oncol
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695479
4.
Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma.
Esophagus
; 21(1): 51-57, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082188
5.
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
Cancer
; 128(11): 2148-2158, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35319779
6.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Lancet
; 398(10302): 759-771, 2021 08 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454674
7.
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
Eur J Immunol
; 51(4): 956-964, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33506525
8.
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.
Invest New Drugs
; 40(2): 265-273, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34973117
9.
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Oncology
; 100(4): 228-237, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196661
10.
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Cancer
; 127(16): 3019-3028, 2021 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826761
11.
MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.
Eur J Immunol
; 50(11): 1810-1819, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510574
12.
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Cancer Immunol Immunother
; 70(5): 1203-1211, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33123755
13.
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model.
Nanomedicine
; 37: 102415, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34174421
14.
Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study.
J Med Internet Res
; 23(8): e28695, 2021 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34448714
15.
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Cancer
; 126(11): 2704-2712, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154925
16.
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Cancer
; 126(17): 4002-4012, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32584426
17.
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Br J Cancer
; 123(12): 1720-1729, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32963347
18.
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
Invest New Drugs
; 38(2): 360-368, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31124056
19.
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
BMC Cancer
; 20(1): 727, 2020 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758163
20.
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Jpn J Clin Oncol
; 50(5): 594-601, 2020 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32083304